Mirum Banks on Livmarli, Overdependence a Concern - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC )
Mirum Pharmaceuticals, Inc.'s MIRM lead product, Livmarli ( maralixibat ) , an orally administered ileal bile acid transporter ( "IBAT" ) inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome ( ALGS ) worldwide.
| Ticker |
Sentiment |
Impact |
|
TVTX
|
Neutral
|
6 %
|
|
MIRM
|
Neutral
|
29 %
|
|
ILMN
|
Somewhat Bullish
|
18 %
|
|
FULC
|
Neutral
|
24 %
|
